Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with significant revenue growth in patient affordability and plasma segments, improved gross profit margins, and increased income before taxes. The Q&A session highlights confidence in future program additions and capacity to handle growth, although some uncertainty exists regarding non-pharmaceutical programs and FDA approval. Operating expenses are well-managed, and despite no share repurchases, cash reserves are earmarked for strategic uses. The overall sentiment is positive, with expectations for continued revenue growth and operational efficiency.
Key Financial Performance
Revenue Revenue grew 50.8% to $28 million, exceeding the high end of guidance provided in March. This growth was driven by strong performance across the patient affordability and plasma donor compensation businesses.
Net Income Net income increased 110% to $5.4 million. This increase reflects the operating leverage inherent in the business as it scales across healthcare and financial ecosystems.
Adjusted EBITDA Adjusted EBITDA increased 113% to $10.6 million. This growth demonstrates the company's ability to scale efficiently and improve profitability.
Operating Margins Operating margins increased 1,040 basis points or 10.4% year-over-year. This improvement highlights the operating leverage and efficiency gains achieved as the business scales.
Patient Affordability Revenue Revenue grew 82% year-over-year to $15.7 million. This growth was driven by new programs launched, organic growth within existing programs, and the ramp-up of large pharmaceutical clients.
Financial Assistance Delivered The patient affordability business delivered more than $540 million in financial assistance to patients, up from approximately $320 million in the first quarter of last year. This growth reflects an increased number of patients served and the expanding role of the business in supporting access to high-cost therapies.
Plasma Revenue Plasma revenue increased 24.9% year-over-year to $11.7 million. This growth was supported by increased efficiency in plasmapheresis processes and higher average monthly revenue per center.
Gross Profit Margin Gross profit margin expanded to 65% from 62.9% in the first quarter of 2025. This improvement was driven by a greater mix of higher-margin Pharma revenue.
Operating Expenses Total operating expenses increased 25.5% to $11.6 million, which was well below the revenue growth rate of 50.8%. This reflects disciplined cost management and operating leverage.
Income Before Taxes Income before taxes increased to $7.5 million from $3.3 million in the first quarter of 2025. This growth was driven by strong revenue performance and improved operating margins.
Adjusted EBITDA Margin Adjusted EBITDA margin expanded to 37.8% from 26.7% a year ago. This reflects improved profitability and operating efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Patient Affordability Programs: Revenue grew 82% year-over-year to $15.7 million, driven by new programs, organic growth, and ramp-up of pharmaceutical clients. 4 new programs launched in Q1, bringing total active programs to 135. Delivered $540 million in financial assistance to patients, up from $320 million in Q1 2025.
Plasma Donor Compensation Business: Revenue increased 25% year-over-year to $11.7 million. Advances in plasmapheresis hardware improved efficiencies. Exited Q1 with 573 centers, 22 less than 2025 due to closures and sales, but no expected negative financial impact.
International Expansion: Engaged with plasma collectors and device manufacturers in the U.S., Europe, and Asia. Progress made in SaaS solutions and direct integration with plasmapheresis devices, streamlining operations and reducing errors.
Operating Margins: Increased by 10.4% year-over-year, demonstrating scalability and operational leverage.
Gross Profit Margin: Expanded to 65% from 62.9% in Q1 2025, driven by a higher mix of Pharma revenue.
Cost Management: Operating expenses grew 25.5%, well below revenue growth of 50.8%, showcasing operational efficiency.
Strategic Direction Validation: Pharma surpassed plasma as the largest revenue contributor, reflecting strategic focus on patient affordability.
Pipeline Strength: Robust pipeline with confidence in exceeding 2025 program additions. Closed new business at ASX 26 summit, reinforcing demand and growth outlook.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Plasma Center Closures: Several low-performing plasma centers were closed or sold, reducing the total number of centers by 22 compared to the end of 2025. While the company expects donors to transition to other centers, there is a potential risk of disruption in plasma revenue if this transition does not occur as anticipated.
Customer Loss in Plasma Business: A customer sold all their plasma centers to a competing provider, resulting in a loss of 16 centers and approximately $650,000 in annual revenue. This could impact the company's ability to grow its plasma business.
Operational Constraints in Q1: The first quarter is described as the most operationally constrained period due to plan year transitions, formulary changes, and deductible resets. These constraints could impact the company's ability to efficiently scale and manage operations during this period.
Dependence on Pharma Revenue Growth: The company’s increasing reliance on pharma revenue, which now surpasses plasma revenue, poses a risk if growth in the pharma segment slows or if there are disruptions in the pharmaceutical industry.
Seasonality in Revenue Streams: Pharma revenues are highest in Q1 due to insurance deductible resets, while plasma revenues are softest in Q1 and build throughout the year. This seasonality could lead to uneven financial performance across quarters.
Regulatory and Industry Challenges: The company operates in highly regulated industries (pharma and plasma), which could face changes in regulations or industry practices that may adversely affect operations or financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Paysign expects full-year revenue to be in the range of $106.5 million to $110.5 million, representing 30% to 35% year-over-year growth.
Gross Profit Margins: Gross profit margins are projected to be between 60% and 62% for the full year 2026.
Net Income and Adjusted EBITDA: Net income is expected to range from $13 million to $16 million, or $0.21 to $0.26 per diluted share. Adjusted EBITDA is projected to be between $30 million and $33 million, or $0.49 to $0.53 per diluted share.
Active Patient Affordability Programs: Paysign anticipates having 147 to 150 active patient affordability programs by the end of the second quarter of 2026.
Active Plasma Center Count: The active plasma center count is expected to decline to 555 to 560 centers due to the closure of 19 underperforming centers in May 2026. However, no financial impact is expected as cardholders are anticipated to transition to other centers.
Seasonality in Revenue: Pharma revenues are expected to be highest in the first quarter and moderate throughout the year, while plasma revenues are anticipated to build through the year after a soft first quarter.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is driving the confidence in exceeding 55 net program adds in 2025?
A:The pipeline shows a good mix of around 50-50 between entirely new clients and growth within existing clients. There is no single inflection point; rather, it is a result of building on the foundation laid earlier. The company has a larger client base and continues to bring new clients onto the platform.
Q:Does the company have the capacity to handle 190 programs by 2026?
A:Yes, the company has robust IT systems and high-availability infrastructure to handle growth. They will continue hiring for account management but do not foresee any additional requirements to support the growth.
Q:What is the outlook for plasma revenue in Q2 and the rest of the year?
A:Plasma revenue is expected to grow sequentially throughout the year. The company has seen early indications of recovery from the inventory overhang experienced in 2025. Some underperforming centers were closed, but this is not expected to impact overall numbers as cardholders will move to other nearby centers.
Q:How many pharma programs does the company currently have, and what is the projection for Q2?
A:The company exited the quarter with 135 programs and currently has 141 active programs. By the end of Q2, they expect to have between 147 and 150 active programs.
Q:What are the competitive advantages of the plasma platform and app?
A:The platform integrates various modules like the app, CRM, and qualitative analysis, providing seamless communication and less friction for plasma centers. It enhances ease of use and donor engagement. The company does not see any competitors with similar technological capabilities.
Q:What is the mix of new wins between new clients and existing clients?
A:Approximately 50% of new wins come from existing clients adding programs, while the other 50% are from new clients. The company expects more transitions than new product launches this year but is confident in meeting guidance targets.
Q:Why does incremental adjusted EBITDA conversion drop in the next three quarters?
A:The drop is due to a mix shift, with more plasma revenue expected compared to patient affordability. Seasonal factors remain unchanged, and the guidance already accounts for this mix shift.
Q:Is the SaaS and app generating revenue, and has it been approved by the FDA?
A:No, the SaaS and app are not generating revenue yet. Discussions with the FDA are ongoing, and updates will be provided in the future.
Q:Are there any updates on non-pharmaceutical programs on the payment side?
A:The company has targets for non-pharmaceutical programs but considers it premature to discuss them at this time.
Q:What are the company’s plans for its cash reserves?
A:The company has no material obligations beyond $6 million in payments to Gamma over the next three years. They plan to hold onto the cash for potential acquisitions, shareholder redistribution, or other uses.
Q:Were there any share repurchases in the quarter?
A:No, there were no share repurchases in the quarter.
Q:Review of Unclear Management Responses
A:The management avoided providing specific details on the status of non-pharmaceutical programs and the FDA approval process for the SaaS and app. They also did not elaborate on the targets for non-pharmaceutical programs, citing it as premature to discuss.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASX
Assembia
Chief
Europe Asia
Officer
affordability
benefit
capacity
center
client
closure
collection company
collector
conversation
day
demand
device manufacturer
donor
health care
increase
industry
integration
opportunity
partner
patient therapy
payer
pharmaceutical manufacturer
plasma collection
plasmapheresis device
platform
process
solution
start
step
value
PAYS Transcript
Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript
Positive5-13
The earnings call reveals strong financial performance with significant revenue growth in patient affordability and plasma segments, improved gross profit margins, and increased income before taxes. The Q&A session highlights confidence in future program additions and capacity to handle growth, although some uncertainty exists regarding non-pharmaceutical programs and FDA approval. Operating expenses are well-managed, and despite no share repurchases, cash reserves are earmarked for strategic uses. The overall sentiment is positive, with expectations for continued revenue growth and operational efficiency.
Paysign, Inc. (PAYS) Q4 2025 Earnings Call Transcript
Unknown3-25
Despite strong financial performance with increased revenue, net income, and improved gross margin, the lack of strategic initiatives and operational updates, coupled with forward-looking risks, creates uncertainty. The absence of discussion on returns and strategic outlook further limits positive sentiment. Without market cap data, a neutral prediction is prudent, balancing financial strength against potential risks.
Paysign, Inc. (PAYS) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call indicates strong growth prospects, with significant year-over-year improvements in financial metrics, increased revenue guidance, and operational efficiencies. The Q&A section supports optimism with plans for new programs and systems, despite management's lack of specific details. The raised revenue guidance and anticipated FDA approval for new systems suggest positive momentum. However, the lack of clear guidance on some metrics and confidentiality constraints slightly temper the outlook, preventing a 'Strong positive' rating.
Paysign, Inc. (PAYS) Q2 2025 Earnings Call Transcript
Positive8-5
The company's earnings call indicates strong financial performance, with significant revenue growth and improved margins driven by the patient affordability business. Despite some decline in plasma revenue, the overall outlook is optimistic with a promising pipeline of new programs and operational efficiencies. The Q&A section suggests positive sentiment from analysts, with inquiries focused on growth and expansion. The strategic acquisition and efficient operations further enhance prospects, leading to a positive stock price prediction.
PAYS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
